SCI Abstract

search
+
Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells
Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with poor prognosis and limi...
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks
In Japan, atezolizumab is indicated for several cancers at a dose of 1200 mg every 3 weeks or 840 mg eve...
Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma
Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) presents a great challenge in the clinic due to its poor prognosis. Prior research h...
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors
Interleukin (IL)-1 signaling has an essential role in tumor progression and immunosuppression and is linked to acquired re...
Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study
Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study
Pleural mesothelioma (PM) is a rare cancer affecting the pleural layer on the body’s serosal surfaces. Exposure to a...
MicroRNA nanoformulation: a promising approach to anti-tumour activity
MicroRNA nanoformulation: a promising approach to anti-tumour activity
Cancer is a major cause of morbidity and mortality, making it one of the most debilitating diseases in our time. Despite a...
Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia
Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia
Acute myeloid leukemia (AML) is a relapsing and drug-resistant hematologic malignancy. We report AB138, a novel molecular ...
TP53 and DNA-PK as potential biomarkers for enhanced efficacy of Olaparib in colorectal cancer
TP53 and DNA-PK as potential biomarkers for enhanced efficacy of Olaparib in colorectal cancer
Olaparib is selected based on the presence of BRCA mutations in patient populations; however, further investigation is sti...
Medulloblastoma associated with Lynch syndrome: a case report of germline variant and tumor molecular characterization
Medulloblastoma associated with Lynch syndrome: a case report of germline variant and tumor molecular characterization
Lynch syndrome (LS) is an autosomal autosomal dominant inherited disease characterized by impaired DNA mismatch repair (dM...
Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition
Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition
Mitochondrial dysfunction is a key driver of cancer progression, with therapies increasingly targeting metabolic weaknesse...
Orelabrutinib combined with rituximab and high-dose methotrexate as induction therapy in newly diagnosed primary central nervous system lymphoma
Orelabrutinib combined with rituximab and high-dose methotrexate as induction therapy in newly diagnosed primary central nervous system lymphoma
Limited treatment options for primary central nervous system lymphoma (PCNSL) highlight the need for alternative therapies...
The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment
The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment
Our study aims to target Met and EpCAM to inhibit angiogenesis in breast cancer, particularly triple-negative breast cance...
Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis
Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis
Central nervous system lymphoma (CNSL) are mainly diffuse large B-cell lymphomas (DLBCLs). Orelabrutinib is a second-gener...
Approval of high-benefit oncology drugs in Japan: utilization of expedited regulatory pathways for the accelerated approved anticancer drugs
Approval of high-benefit oncology drugs in Japan: utilization of expedited regulatory pathways for the accelerated approved anticancer drugs
Early access to promising new drugs with superior efficacy compared to existing treatments is globally sought after. To fa...
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors
Onivyde, a liposome-encapsulated irinotecan, is used for advanced pancreatic, while TAS-102 (trifluridine/tipiracil) is in...
A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer
A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer
Despite advances in cancer treatment, chemotherapy remains a cornerstone of clinical practice. However, its efficacy is of...
Clinical characterizations, management, and prognosis in immune checkpoint inhibitor-induced myelitis
Clinical characterizations, management, and prognosis in immune checkpoint inhibitor-induced myelitis
The expanding clinical application of immune checkpoint inhibitors (ICIs) has led to increasing recognition of neurologica...
Research progress on cancer-related epigenetic switches
Research progress on cancer-related epigenetic switches
The dysregulation of cellular epigenetic machinery has been established as a fundamental driver of oncogenesis. This recog...
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
In recent years, a number of novel pharmaceutical agents have received approval for the management of acute myeloid leukem...
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects
Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This...
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells
This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, As...
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function
Gastric cancer (GC) is widely regarded as one of the toughest cancers to treat. Trastuzumab, which targets the human epide...
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis
Nivolumab can cause fatal myocarditis. We aimed to analyze the clinical characteristics of nivolumab-induced myocarditis a...
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Navitoclax (ABT-263) is an oral BCL2 homology-3 mimetic that binds with high affinity to pro-survival BCL2 proteins, resul...
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Part E of the KEYNOTE-011 (NCT01840579) study assessed the safety and antitumor activity of pembrolizumab plus platinum-et...
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
C-X-C motif chemokine receptor 2 (CXCR2) has a role in tumor progression, lineage plasticity, and reduction of immune chec...
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma
Identifying biomarkers to evaluate the therapeutic effect of immune checkpoint inhibitors (ICIs) is crucial. Regulatory As...
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis
Gastritis has recently been reported to be associated with nivolumab, and the clinical characteristics of nivolumab induce...
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-
Dexamethasone is one of the key antiemetic agents and is widely used even now. However, dexamethasone has been associated ...
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Indoleamine-2,3-dioxygenase (IDO) helps orchestrate immune suppression and checkpoint inhibitor resistance in hepatocellul...
Load More
format_indent_increase